- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 133,26 | +1,46 % | Dividendenbekanntmachungen (15.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AKVA GROUP ASA NO0003097503 1 NOK 0,0927 EUR ALEXANDRIA GROUP OYJ FI4000153465 - 0,35 EUR ALTRIA GROUP INC US02209S1033 1,11 USD 0... ► Artikel lesen | |
| ZOETIS | 63,30 | +1,74 % | Zoetis unter Druck: Was Stifel jetzt befürchtet | ||
| INCYTE | 109,00 | +0,23 % | Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio | Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held... ► Artikel lesen | |
| AMARIN | 11,500 | -0,86 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,936 | +44,67 % | XFRA PX91: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFILANA THERAPEU.... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 250,00 | +1,63 % | Ligand Pharmaceuticals: Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea from Sydnexis for $23 Million | Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 7,200 | 0,00 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 465,80 | +2,49 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ANI PHARMACEUTICALS | 67,50 | -2,17 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors | - Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company - PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company)... ► Artikel lesen | |
| TALPHERA | 1,010 | -0,98 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 40,350 | +0,65 % | Rigel Pharmaceuticals, Inc.: Rigel Reports Second Quarter 2026 Financial Results | Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and... ► Artikel lesen | |
| SAVARA | 4,637 | -0,04 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| ARTIVION | 20,400 | +0,99 % | Artivion, Inc.: Artivion Reports Second Quarter 2026 Financial Results | Second Quarter & Recent Business Highlights:
Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,680 | +0,01 % | Biodexa Pharmaceuticals enters warrant exercise transaction for $2.3M gross proceeds; shares rise | ||
| HERON THERAPEUTICS | 0,253 | 0,00 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen |
Das Unternehmen CORNERSTONE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.